RPG Life Sciences Limited (NSE:RPGLIFE)

Market Cap	43.14B +8.2%
Revenue (ttm)	7.34B +11.8%
Net Income	1.20B -34.5%
EPS	72.33 -34.5%
Shares Out	16.54M
PE Ratio	36.06
Forward PE	34.65
Dividend	24.00 (0.92%)
Ex-Dividend Date	Jul 9, 2026

Volume	14,373
Open	2,754.00
Previous Close	2,780.20
Day's Range	2,558.00 - 2,781.60
52-Week Range	1,733.00 - 3,127.80
Beta	-0.13
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 16, 2026

About RPG Life Sciences

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and domestic and international finished dosage formulations for various therapies, which inclu...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1968
• Employees: 1,366
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: RPGLIFE

Financial Performance

In fiscal year 2026, RPG Life Sciences's revenue was 7.08 billion, an increase of 8.28% compared to the previous year's 6.53 billion. Earnings were 1.15 billion, a decrease of -37.15%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 23, 2026

Data Sources Report a data error